Clavis Pharma and Mount Sinai School of Medicine (MSSM) have entered into a collaborative development agreement on potential new cancer drugs.
The collaboration relates to the development and testing of new drugs, based on Clavis’ Lipid Vector Technology for the treatment of cancer and haematological malignancies.
Clavis will be responsible for identifying and synthesizing new compounds and MSSM will be responsible for in vitro and in vivo experiments. Clavis has already synthesized the first drug covered by the agreement, and studies by MSSM will start immediately.
Under the terms of the agreement, Clavis Pharma has been granted exclusive, worldwide rights for all potential products being developed during the collaboration. MSSM will receive royalties on future sales.